Cytek BioSciences, Inc. (CTKB): Price and Financial Metrics Recent IPO

Cytek BioSciences, Inc. (CTKB): $24.72

-1.25 (-4.81%)

POWR Rating

Component Grades













CTKB Stock Price Chart Interactive Chart >

Price chart for CTKB

CTKB Price/Volume Stats

Current price $24.72 52-week high $28.70
Prev. close $25.97 52-week low $17.40
Day low $24.29 Volume 375,900
Day high $27.09 Avg. volume 366,395
50-day MA $0.00 Dividend yield N/A
200-day MA $0.00 Market Cap 3.30B

Cytek BioSciences, Inc. (CTKB) Company Bio

Cytek Biosciences, Inc. engages in the manufacture and sale of cell analysis solutions for clinical and biomedical research in the fields of drug discovery, genomics, immuno-oncology, immuno-profiling, infectious diseases, inflammatory diseases, and multi-site standardization applications. Its instruments include the Aurora and Northern Lights systems, which are flow cytometers to deliver cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. The company also offers cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. Its customers include pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. Cytek Biosciences, Inc. was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. The company was incorporated in 2014 and is headquartered in Fremont, California.

CTKB Latest News Stream

Event/Time News Detail
Loading, please wait...

CTKB Latest Social Stream

Loading social stream, please wait...

View Full CTKB Social Stream

Latest CTKB News From Around the Web

Below are the latest news stories about Cytek Biosciences Inc that investors may wish to consider to help them evaluate CTKB as an investment opportunity.

Cytek Biosciences Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

FREMONT, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, announced today that the underwriters of its previously announced initial public offering, which closed on July 27, 2021, have exercised in full their option to purchase 2,184,695 additional shares of common stock at the price to the public of $17.00 per share. With the addition of the full exercise of the underwriters’ option to p

Yahoo | August 2, 2021

Cytek Biosciences Announces Closing of Its Initial Public Offering

FREMONT, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, announced today the closing of its initial public offering of an aggregate of 14,564,635 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds to Cytek from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were $200 million. The offering con

Yahoo | July 27, 2021

Cell Analysis Instruments Provider Cytek Biosciences Kick Starts Trading After Pricing IPO At $17

Cytek Biosciences Inc (NASDAQ: CTKB) shares started trading today after its initial public offering was priced to raise about $200 million for the cell-analysis Company. Cytek has developed high-resolution, high-content, and high-sensitivity cell analysis technology called Full Spectrum Profiling. Supported by the firm's Aurora and Northern Lights systems, a cell sorter called the Aurora CS allows a higher level of multiplexing than traditional flow cytometry. Apart from the Northern Lights CLC

Yahoo | July 23, 2021

Read More 'CTKB' Stories Here

CTKB Price Returns

1-mo 10.36%
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.72 seconds.